Evidence map›Paper›PMID 40728408›Full record

ArticleMicrobiology spectrum2025

A tool of the trade for a newly identified filovirus: pseudovirus-based system for Dehong virus entry and neutralization.

Banhi Biswas

Abstract readComment
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Banhi BiswasDepartment of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0002-7478-5547

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudovirus-based assays are efficient and accessible platforms for measuring neutralizing antibody titers and screening antiviral drugs against enveloped viruses. They typically employ two types of packaging systems, retroviral-based or vesicular stomatitis virus (VSV)-based systems. These systems have been validated for several high-risk pathogens, including Ebola, Marburg, Dengue and, more recently, SARS-CoV-2, as they offer a safe alternative for studying high-containment viruses. In a recent study (Wu X, Liu F, Li T, Li D, Shen Y, Zhang X, Liu S, Jiang Q, Zhao C, Nie J, Wang Y, Feng B, Liu W, Huang W, Microbiol Spectr, 13:e01557-24, 2025, https://doi.org/10.1128/spectrum.01557-24), Wu and colleagues developed a pseudovirus system and optimized it for neutralization assays targeting the newly identified Dehong virus (DEHV). The authors also utilized this system to detect bioluminescent signals in mouse models. Importantly, using this pseudovirus platform, they confirmed that Niemann-Pick C1 (NPC1) functions as the entry receptor for DEHV, consistent with prior findings using infectious viruses. This work provides valuable insights into the limited understanding of DEHV biology.

Indexed as

Antibodies, NeutralizingFiloviridaeNeutralization TestsVirus InternalizationAnimalsAntibodies, ViralAntiviral AgentsHumansMiceSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntiviral AgentsDehong virusneutralization assaypseudovirus

Identifiers

PMID40728408
PMCPMC12403848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.